ATE232386T1 - Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung - Google Patents

Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung

Info

Publication number
ATE232386T1
ATE232386T1 AT95943647T AT95943647T ATE232386T1 AT E232386 T1 ATE232386 T1 AT E232386T1 AT 95943647 T AT95943647 T AT 95943647T AT 95943647 T AT95943647 T AT 95943647T AT E232386 T1 ATE232386 T1 AT E232386T1
Authority
AT
Austria
Prior art keywords
linear
branched
branched alkyl
co2h
conjugates
Prior art date
Application number
AT95943647T
Other languages
English (en)
Inventor
Samuel J Danishefsky
Matthew D Shair
Taeyoung Yoon
Ting-Chao Chou
Karoline K Mosny
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE232386T1 publication Critical patent/ATE232386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95943647T 1994-12-01 1995-12-01 Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung ATE232386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/347,952 US5622958A (en) 1994-12-01 1994-12-01 Enediyne quinone imines and methods of preparation and use thereof
PCT/US1995/015678 WO1996016655A1 (en) 1994-12-01 1995-12-01 Novel enediyne quinone imines and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
ATE232386T1 true ATE232386T1 (de) 2003-02-15

Family

ID=23366001

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95943647T ATE232386T1 (de) 1994-12-01 1995-12-01 Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung

Country Status (6)

Country Link
US (2) US5622958A (de)
EP (1) EP0793497B1 (de)
AT (1) ATE232386T1 (de)
AU (1) AU715168B2 (de)
DE (1) DE69529624D1 (de)
WO (1) WO1996016655A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003124A1 (en) * 1994-07-27 1996-02-08 California Institute Of Technology Dynemicin analogs
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6787150B2 (en) * 2002-07-22 2004-09-07 Kes Associates Seed coating for bypassing the ruminant digestive tract
EP2476441A1 (de) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Verfahren und Reagenzien zur effizienten und gezielten Abgabe von therapeutischen Molekülen an CXCR4-Zellen
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
EP2930238A1 (de) 2014-04-09 2015-10-14 Fundacio Centre de Regulacio Genomica Zusammensetzungen zur Behandlung von Krebs
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3427756A1 (de) 2017-07-14 2019-01-16 Universidad Autónoma De Barcelona (UAB) Therapeutische nanokonjugate und verwendungen davon
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3842452A1 (de) 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Gerüstproteine und therapeutische nanokonjugate auf nidogenbasis
WO2024105116A1 (en) 2022-11-15 2024-05-23 Universitat Autònoma De Barcelona NANOCONJUGATES CONTAINING PDGFR-β LIGANDS AND USES THEREOF
WO2024151672A1 (en) * 2023-01-09 2024-07-18 The Johns Hopkins University Directed biosynthesis of modified anthraquinone-fused enediynes as potential cancer therapeutics
EP4724485A1 (de) 2023-06-07 2026-04-15 Universidad del País Vasco/Euskal Herriko Unibertsitatea Rückverpackte antikörperkonstrukte und deren verwendungen
WO2026078018A1 (en) 2024-10-07 2026-04-16 Fundación Para La Investigación Médica Aplicada Cd33 specific single domain antibodies (sdab), cars and other products derived therefrom, and their uses in therapy and diagnosis
WO2026078266A1 (en) 2024-10-11 2026-04-16 Fundacion Para La Investigacion Medica Aplicada Bcma specific single domain antibodies (sdab), cars and other products derived therefrom, and their uses in therapy and diagnosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276159A (en) * 1990-08-01 1994-01-04 The Scripps Research Institute Dynemicin analogs: syntheses, methods of preparation and use
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
WO1996003124A1 (en) * 1994-07-27 1996-02-08 California Institute Of Technology Dynemicin analogs

Also Published As

Publication number Publication date
AU4506896A (en) 1996-06-19
US5622958A (en) 1997-04-22
WO1996016655A1 (en) 1996-06-06
EP0793497B1 (de) 2003-02-12
AU715168B2 (en) 2000-01-20
EP0793497A1 (de) 1997-09-10
DE69529624D1 (de) 2003-03-20
EP0793497A4 (de) 1998-01-28
US6020341A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
DE69529624D1 (de) Neue endiyn-chinonimine und verfahren zu deren herstellung und verwendung
DK0749432T3 (da) 9-deoxotaxan-forbindelser
DK0639186T3 (da) Taxolderivater
PL295030A1 (en) Method of obtaining substituted derivatives of 2-cyclohexan-1-yl amine
DE59102030D1 (de) Liposomen mit positiver überschussladung.
MX9708621A (es) AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.
YU89691A (sh) Postupak za dobijanje stereoselektivnih derivata fenilizoserina
NZ505103A (en) Phenylaminoalkylcarboxylic acid derivatives useful as beta 3 adrenoceptor stimulants
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
EP0774462A4 (de) Heterocyclische verbindungen
EP0490816A3 (en) Fluoro-compounds
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
DE69330601D1 (de) Serotoninergische ergolin derivate
BG103735A (en) Method for the preparation of substituted thiazolidindions
ATE188217T1 (de) 1,2,3,4,10,14b-hexahydrodibenzo-c,f)pyrazino-1, - a)azepino-derivate
PT97571A (pt) Processo para a prparacao de hidrazonas
PT90492A (pt) Processo para a preparacao de novos eicosanoides sulfurados e sua aplicacao em farmacia e em cosmeticos
FI953784A0 (fi) 3'-atsiridinoantrasykliinijohdannaiset
CA2188176A1 (fr) (oxo-1 alkyl) amino-2, deoxy-2 glucopyranoside de dihydroxy - 2,3 propyl, leur procede de preparation et leurs utilisations
ATE247955T1 (de) Selenophen-antitumormittel
PT98976A (pt) Processo para a preparacao de heteroarilmetilbenzenos
KR870007201A (ko) 헵타노일- glu-asp-ala-아미노산 면역 자극물질
AUPP109097A0 (en) Napthalene derivatives
ATE118763T1 (de) Phenolisches amin als antimelanoma- und depigmentierungsmittel.
PL246418A1 (en) Process for preparing n-/3-trifluoromethylphenyl/-n'-propargylpiperazine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties